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Abstract 
A 57-year-old Japanese woman with schizophrenia, who had received long-term 
treatment with neuroleptics, noticed a painless, pea-sized lump in her right breast. She 
was admitted to our hospital and a malignant tumor was diagnosed. The patient 
underwent a conservative radical mastectomy (Patey’s operation). The excised tumor 
measured 2.0 × 1.2 × 1.1 cm in diameter, and its cut surface was grayish-white. 
Histologically, tumor cells with clear to foamy cytoplasm were invariably Oil Red O-
positive and periodic acid Schiff-negative with or without diastase digestion. The tumor 
was diagnosed as a lipid-rich carcinoma accompanied by an in situ component. 
Neuroleptics increase serum prolactin levels by interfering with dopaminergic inhibition 
of prolactin secretion. Immunohistochemical analysis revealed that, although prolactin 
was not detected, the tumor cells expressed prolactin receptor, indicating prolactin as 
the genesis of this neoplasm. In immunohistochemical intrinsic subtype analysis, the 
tumor was negative for estrogen receptor, progesterone receptor, human epidermal 
growth factor receptor 1 and 2, and basal cytokeratins (CK5, CK6, and CK14), indicating 
an unclassified (all-marker negative) subtype. Axillary lymph nodes were free of 
metastasis (stage I), and the patient has been well for 20 years without any evidence of 
recurrence. Case Rep Oncol 2011;4:275–280 
DOI: 10.1159/000328804 
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Introduction 
Lipid-rich carcinoma is a very rare histological variant of breast cancer that accounts 
for less than 1% of all breast cancers [1]. It is composed of clear to vacuolated cytoplasm 
with abundant neutral lipid present within 90% of the tumor cells [2]. Lipid-rich 
carcinomas are considered to behave aggressively and have a worse prognosis than other 
types of breast cancer. However, the true behavior of this tumor is not well known. Gene 
expression profiling studies have refined breast cancer classification and identified 
distinct subgroups that have an independent association with patient outcome [3, 4], and 
findings can be surrogated by immunohistochemical markers that match the gene 
expression patterns [5–7]. Here, a case of lipid-rich carcinoma previously included as case 
1 in a series of 13 breast cancer patients who received long-term treatment with 
neuroleptics [8] was re-evaluated to determine the intrinsic immunohistochemical (IHC) 
subtype. The present report describes the histological characteristics and intrinsic subtype 
profile of this case of lipid-rich carcinoma of the breast. 
Case Report 
A 57-year-old Japanese woman who had received long-term neuroleptic treatment for schizophrenia 
noticed a painless, pea-sized lump in her right breast, and she was admitted to our hospital. The tumor 
size was 2.5 × 1.5 cm in diameter, and an excisional biopsy confirmed malignancy (T1N0M0). The 
patient underwent a conservative radical mastectomy (Patey’s operation: Br+Ax+Mn). The excised 
tissue specimens were routinely processed for histological, histochemical, and IHC examinations. 
Briefly, formalin-fixed, paraffin-embedded tissues were deparaffinized and stained with hematoxylin 
and eosin (HE) and periodic acid-Schiff (PAS) with or without diastase digestion. 
Immunohistochemistry was performed with the primary antibodies listed in table 1 and a labeled 
streptavidin biotin staining kit (Dako, Carpinteria, Calif., USA). Frozen sections cut on a cryostat were 
prepared from the formalin-fixed wet tissues and stained with Oil Red O. 
Macroscopically, the excised tumor measured 2.0 × 1.2 × 1.1 cm in diameter, and its cut surface was 
grayish-white. Histologically, tumor cells were large with clear to foamy cytoplasm, accompanied by 
cellular pleomorphism and nuclear atypia. Cancer cells were arranged irregularly in solid clumps and 
nests (fig. 1a) or formed atypical epithelial tufts that protruded into the lumen with desquamated cells 
within the lumen (fig. 1b). Cancer cells were invariably Oil Red O-positive (fig. 1c and d) and PAS-
negative. Immunohistochemically, the tumor cell membranes were positive for E-cadherin (fig. 2a) but 
the tumor cell cytoplasm was negative for basal cytokeratins (CK5, CK6, and CK14). However, basal 
(myoepithelial) cells surrounding the glandular lumen composed of apocrine extrusion of the nuclei 
were positive for CK5 (fig. 2b), CK14, and α-smooth muscle actin (α-SMA). Cancer cells were prolactin 
(Prl)-negative, whereas the prolactin receptor (PrlR) showed cytoplasmic staining (fig. 2c). Cancer cells 
were invariably negative for estrogen receptor (ER), progesterone receptor (PgR), epidermal growth 
factor receptor 1 (HER1), and HER2. Cancer cell invasion was seen in the mammary fat pad, but vessel 
invasion was not seen. Adjacent non-cancerous mammary gland showed diffuse and extensive secretory 
activity. All 16 right axillary lymph nodes were free of metastasis. The patient has remained cancer-free 
for 20 years without any evidence of recurrence. 
Discussion 
Prl contributes to the growth of normal and malignant breast tissues. Long-term 
neuroleptic usage produces a persistent and marked elevation of serum Prl levels, which 
results in secretory activity in the breast [8]. PrlR is a transmembrane protein that consists 
of extracellular, transmembrane, and intracellular domains, and Prl acts through the PrlR. 
Monoclonal antibody B6.2 is directed against the extracellular domain of human PrlR [9]. Case Rep Oncol 2011;4:275–280 
DOI: 10.1159/000328804 
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Although cancer cells were Prl-negative, they were positive for PrlR, which indicates that 
Prl might have played an important role in the development of the lipid-rich carcinoma 
of the breast mediated through the PrlR pathway. The lipid-rich carcinoma contained a 
large amount of neutral lipid but did not contain glycogen or mucin. Secretory 
carcinomas, apocrine carcinomas and glycogen-rich carcinomas are also composed of 
clear to vacuolated cancer cells. A PAS-negative reaction can differentiate lipid-rich 
carcinomas from these other histological types of carcinomas. Additionally, in the present 
case, α-lactalbumin was diffusely positive in the cytoplasm of cancer cells lining the 
glandular lumina [8]. Histologically, lipid-rich carcinomas contain in situ areas and 
invasive areas. In situ areas contain cells arranged in an alveolar pattern with a hobnail 
appearance, in which the luminal borders exhibit apocrine-type cytoplasmic blebs and 
extrusion of hyperchromatic pleomorphic nuclei. Invasive areas contain cells with clear 
and foamy cytoplasm arranged in sheets, nests, and cords [1, 10, 11]. Basal cells in the 
breast express high-molecular-weight basal CKs including CK5/6 and CK14 [12, 13], and 
α-SMA is a marker of myoepithelial differentiation [14]. Foci surrounded by basal 
(myoepithelial) cells indicate an in situ portion, while the lack of these cells indicates an 
invasive portion. The present lipid-rich carcinoma was accompanied by an in situ 
portion. Breast cancer can be distinguished as ductal or lobular in nature, and lipid-rich 
carcinoma can be associated with either ductal or lobular carcinoma in situ [11]. E-
cadherin, a transmembrane glycoprotein that binds similar types of cells together, exists 
in the membranes of cells in ductal lesions while it is lacking in lobular lesions [15]. In the 
present case, the tumor was E-cadherin positive, which suggests that the carcinoma is 
ductal in nature. Lipid-rich carcinomas in the form of ductal carcinoma in situ (DCIS) 
[16] or in the form of an invasive component accompanied with DCIS [17] have been 
reported. 
IHC intrinsic subtypes can be defined by using markers as follows: luminal A (ER+ 
and/or PgR+, HER2–), luminal B (ER+ and/or PgR+, HER2+), HER2-enriched (ER–, 
PgR–, HER2+), and triple negative (ER–, PgR–, HER2–). The triple-negative subtype can 
be further divided into basal-like (ER–, PgR–, HER2–, CK5/6+, and/or HER1+) and 
unclassified (negative for all five markers) [5–7]. According to this system, the present 
case is the unclassified subtype. Due to the rarity of lipid-rich carcinomas, the association 
between intrinsic subtypes and aggressiveness has not been extensively studied. In one 
study, 5 of 6 (83.3%) lipid-rich carcinomas were ER+ and/or PgR+, while 3 of 6 (50%) 
lipid-rich carcinomas were HER2+ [18]. In a study of 17 lipid-rich carcinomas, 1 tumor 
was ER+ and/or PgR+, and all 17 carcinomas were HER2+ [19]. In a third study, 5 of 49 
(10.2%) lipid-rich carcinomas were ER+ and/or PgR+ and 35 of 49 (71.4%) lipid-rich 
carcinomas were HER2+ [20]. Thus, the positive rate of ER and/or PgR tended to be low, 
and HER2 expression tended to be high in these studies of lipid-rich carcinomas. 
According to IHC intrinsic subtype analysis, patients who have HER2-enriched and 
triple-negative subtype cancers have a significantly shorter disease-free survival period 
than patients with other subtypes [7]. The poor prognosis among triple-negative cases is 
conferred almost entirely in basal-like breast cancer [21]. Breast carcinoma with basal 
differentiation can be defined based on the expression of basal CK, such as CK5, CK6, and 
CK14 [13], and lipid-rich carcinoma with a basal cell phenotype (ER–, PgR–, HER2–, 
high molecular weight CK+, HER1+) has been reported [22]. Although the lipid-rich 
carcinoma in the present case report was ER- and PgR-negative, it was also negative for 
HER2 and basal cell CKs, and the patient remains disease-free 20 years after the surgery. Case Rep Oncol 2011;4:275–280 
DOI: 10.1159/000328804 
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Therefore, in lipid-rich carcinoma, like in other histologic types of breast carcinomas, 
HER2 and basal-like subtypes may indicate the aggressive behavior of the neoplasm.  
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Table 1. Antibodies used in the present study 
Antibody Clone  Source 
E-cadherin M106  Takara  (Otsu,  Japan) 
CK5  XM26  Novocastra (Newcastle upon Tyne, UK) 
CK6 LHK6B  Novocastra 
CK14 LL002  Novocastra 
α-SMA  1A4  Dako (Glostrup, Denmark) 
Prl Polyclonal  Dako   
PrlR  B6.2  LifeSpan Biosciences (Seattle, Wash., USA) 
ER 6F11  Novocastra 
PgR  PR10A9  Biodesign (Saco, Me., USA) 
HER1 EGFR.25  Novocastra 
HER2  Polyclonal   Dako  
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Fig. 1. Lipid-rich carcinoma. a Cancer cells with clear and foamy cytoplasm grow in solid clumps and 
nests (HE, ×200). b Cancer cells arranged in an alveolar pattern with a hobnail appearance show 
apocrine-type cytoplasmic blebs and extrusion of hyperchromatic pleomorphic nuclei (HE, ×200). 
c Large amounts of lipid are seen in cancer cells arranged in solid clumps and nests (Oil Red O, ×200). 
d Cancer cells arranged in an alveolar pattern are filled with lipid (Oil Red O, ×200). 
 
 
 
Fig. 2. Lipid-rich carcinoma. a E-cadherin is expressed in cancer cell membranes (E-cadherin, ×200). 
b Cancer cells are CK5-negative, whereas CK5 was positive in basal (myoepithelial) cells (CK5, ×200). 
c Cytoplasmic prolactin receptor (PrlR) is expressed in cancer cells (PrlR, ×200). 
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